ASX-listed biotech PharmAust has secured a patent in the US relating to the use of its promising anti-cancer drug Monepantel, for the treatment of non-cancerous conditions such as neurodegenerative diseases, diabetes and age-related illnesses. The patent is another move by Perth-based PharmAust to boost its global IP protections and follows the granting of patents in Europe, US, Australia and China.
11/10/2017 - 06:32
PharmAust granted US patent for non-cancer uses of cancer drug
By Matt Birney
11/10/2017 - 06:32
Related Data & Insights
-
-
Rank Company Revenue 128th PharmAust $3.8m 129th ResApp Health $3.8m 130th Emyria $3.8m 132nd Botanix Pharmaceuticals $3.8m 133rd Volt Power Group $3.6m 200 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Data & Insights
Mentioned Organisations
Mentioned People
Related Articles
05 Feb 2024
Board Moves February 5, 2024
28 Aug 2023
Board Moves August 28, 2023
30 Jun 2021
Perth funds progress projects world
Subscribe today for award-winning, unbiased and trusted journalism
Subscription OptionsX